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cAMP amplified exocytosis and insulin secretion
in human and murine pancreatic beta-cells
Anna Edlund1, Jonathan LS Esguerra1, Anna Wendt1, Malin Flodström-Tullberg2† and Lena Eliasson1*†Abstract
Background: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene lead to the disease
cystic fibrosis (CF). Although patients with CF often have disturbances in glucose metabolism including impaired insulin
release, no previous studies have tested the hypothesis that CFTR has a biological function in pancreatic beta-cells.
Methods: Experiments were performed on islets and single beta-cells from human donors and NMRI-mice. Detection
of CFTR was investigated using PCR and confocal microscopy. Effects on insulin secretion were measured
with radioimmunoassay (RIA). The patch-clamp technique was used to measure ion channel currents and
calcium-dependent exocytosis (as changes in membrane capacitance) on single cells with high temporal
resolution. Analysis of ultrastructure was done on transmission electron microscopy (TEM) images.
Results: We detected the presence of CFTR and measured a small CFTR conductance in both human and
mouse beta-cells. The augmentation of insulin secretion at 16.7 mM glucose by activation of CFTR by cAMP
(forskolin (FSK) or GLP-1) was significantly inhibited when CFTR antagonists (GlyH-101 and/or CFTRinh-172)
were added. Likewise, capacitance measurements demonstrated reduced cAMP-dependent exocytosis upon
CFTR-inhibition, concomitant with a decreased number of docked insulin granules. Finally, our studies
demonstrate that CFTR act upstream of the chloride channel Anoctamin 1 (ANO1; TMEM16A) in the regulation of
cAMP- and glucose-stimulated insulin secretion.
Conclusion: Our work demonstrates a novel function for CFTR as a regulator of pancreatic beta-cell insulin secretion
and exocytosis, and put forward a role for CFTR as regulator of ANO1 and downstream priming of insulin granules prior
to fusion and release of insulin. The pronounced regulatory effect of CFTR on insulin secretion is consistent with
impaired insulin secretion in patients with CF.
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The cystic fibrosis transmembrane conductance regu-
lator (CFTR) is a cAMP-regulated chloride channel
that belongs to the family of ATP-binding cassette
(ABC)-transporters [1]. As many other ABC-transporters,
CFTR contains two membrane spanning domains (MSDs)
and two nucleotide binding domains (NBDs) that interact
with ATP. In addition, CFTR has a regulatory domain (R)* Correspondence: lena.eliasson@med.lu.se
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2014that contains several phosphorylation sites. The chloride
selective pore of the channel is formed by the MSDs,
whereas the other domains control channel gating [1].
Apart from being an anion channel, CFTR has been sug-
gested to act as a regulator of other proteins and ion chan-
nels [2] in similarity with other members of the family of
ABC-transporters, such as the sulfonylurea receptor
(SUR1).
CFTR is primarily present in epithelial cells in air-
ways, intestine and in cells with exocrine functions.
Mutations in the gene encoding the channel protein
complex (cftr) cause the autosomal recessive disease
cystic fibrosis (CF). In patients with CF the defectiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of thick viscous mucus caused by a disturbed ion and
water transport across epithelial membranes. The aber-
rant secretory functions cause obstruction of the distal
airways and intestine, pancreatitis and malabsorption
[3].
With increasing lifespan many CF patients develop
cystic fibrosis-related diabetes (CFRD). The mean age of
CFRD onset is around 20 years and the prevalence
varies between 30 to 50% depending on the population
studied [4-7]. Despite an increased awareness of the
clinical impact of CFRD surprisingly little is known
about its etiopathogenesis. CFRD is associated with exo-
crine pancreatic insufficiency caused by duct obstruc-
tion and fibrosis, but not all patients with pancreatic
insufficiency develop diabetes [8,9]. It has been sug-
gested that the endocrine problem is, at least in part,
mechanical [4,9]. Abnormalities in the islet architecture
and beta-cell loss have been observed while alpha- and
delta-cell mass have remained intact or even increased
[10-13]. However, observations showing that CFRD
often correlates with insulin deficiency and/or a signifi-
cant lower first-phase insulin secretion (for example, in
[8,9,14,15]), clearly indicate that other, beta-cell intrinsic
factors, may play a causative role in CFRD. Moreover,
many CF patients, also those without CFRD, have nor-
mal fasting plasma glucose levels, but suffer from post-
prandial hyperglycemia indicating that the beta-cells fail
to respond upon increased insulin demand. A recent
pilot study [16] performed on five CFRD patients with
the G551D mutation having reduced/absent acute insu-
lin response is in support of an insulin secretion defect
in CFRD. One-month treatment with Ivacaftor, a newly
developed CFTR potentiator, increased the insulin
response to oral glucose in four out of the five patients.
On a cellular level, data from insulin secreting HIT-cells
support a role for an ATP-sensitive and cAMP-activated
current in insulin secreting cells [17]. Boom et al.
revealed that CFTR mRNA and protein are expressed
by both alpha- and beta-cells in rats [18], but did not
investigate the physiological importance of CFTR for
the functions of these cells. In the present study, we
have used murine and human pancreatic islets and
single beta-cells to test the hypothesis that active CFTR




Animal procedures were approved by the local ethics
committee for use of laboratory animals in Malmö, Sweden.
Human islet isolation from deceased donors and experi-
mental protocols were approved by the ethics committee
in Uppsala and Malmö, Sweden.Islet isolation and cell culture
Islets from 43 non-diabetic human donors (F/M 18/25,
age 59 ± 1.3, body mass index (BMI) 25.5 ± 0.5 kg/m2,
HbA1c 5.7 ± 0.04, days in culture 4.1 ± 0.3) were used
for secretion measurements, patch-clamp experiments,
qPCR and immunohistochemistry. For these experi-
ments islets were hand-picked to ensure high purity.
Human islets were provided by the Nordic Network for
Clinical Islet Transplantation (Uppsala, Sweden) through
the LUDC Human Tissue Laboratory. Female NMRI
mice (Bolmholtgaard, Ry, Denmark) were sacrificed by
cervical dislocation and islets were isolated by collage-
nase digestion and hand-picked prior to experiments.
For patch-clamp measurements, human and mouse
islets were dispersed into single cells as previously
described [19].mRNA expression measured with RT-qPCR
Total RNA from human and mouse islets were pre-
pared as described [20]. CFTR mRNA expression was
measured by RT-qPCR using primers and probes from
Taqman mRNA assays (Life Technologies, California,
USA). Human CFTR: Hs00357011_m1 expression was
normalized against human HPRT1: 4333768 F, while
mouse CFTR: Mm00445197_m1 expression was normal-
ized against mouse HPRT1: Mm00446968. RT-qPCR runs
were performed for individual batches of human (N = 5)
and mouse (N = 5) islets in triplicate wells of 384-well
plate on a 7900 HT RT-PCR system (Applied Biosystems,
California, USA).Immunocytochemistry
Human or mouse single cells were fixed and stained as de-
scribed elsewhere [21]. Primary antibodies; Mouse monoclo-
nal anti-CFTR (MATG-1061, RD-Biotech, France), Guinea
pig monoclonal anti-insulin (Linco, Billerica, MA, USA),
Guinea pig monoclonal anti-insulin (EuroDiagnostica,
Malmö, Sweden) and rabbit polyclonal anti-Stx1A (Synaptic
Systems, Goettingen, Germany). Secondary antibodies;
guinea pig conjugated to Cy2, mouse conjugated to Cy3,
guinea pig and rabbit conjugated to Cy5 (all from Jackson,
UK). Immunofluorescence was detected with a confocal
microscope (META 510, Zeiss, Germany) and unspecific
binding of the secondary antibodies was excluded by par-
allel experiments in the absence of the primary antibodies.
Localization of CFTR was analyzed as described elsewhere
[22]. In short, the ratio between the mean fluorescent in-
tensity in the plasma membrane region (P1) and the cyto-
solic region (P2) was measured using ZEN software (Zeiss,
Jena, Germany). Pixel by pixel co-localization analysis was
also performed using Zen software. The same laser setting
was retained between experiments enabling comparison
of experiments performed at different occasions.
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EPC10 amplifier and 8.80 pulse software (HEKA, Lambrecht/
Pfalz, Germany) was used to evoke and record whole-cell
currents and changes in membrane capacitance on single
mouse and human islet cells as described [19]. Current
and capacitance measurements were performed at RT and
32 to 33°C, respectively. Extracellular solution contained:
118 mM NaCl, 20 mM TEACl, 5.6 mM KCl, 2.6 mM
CaCl2, 1.2 mM MgCl2, 5 mM HEPES, 3 (current mea-
surements)/5 (capacitance measurements) mM D-glucose
pH 7.4 (NaOH), supplemented with 10 μM FSK, 200 μM
4,4'-Diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS),
10 μM CFTRinh-172 (Sigma Aldrich, Sweden), 25 μM
(current measurements) or 40 μM (capacitance mea-
surements) GlyH-101 (Calbiochem, USA) [23,24] and
50 μM T16Ainh-AO1 (gift from A.S. Verkman, Depart-
ment of Medicine, UCSF School of Medicine) as indi-
cated. The intracellular solution contained: 125 mM
CsOH, 125 mM Glutamate, 10 mM CsCl, 10 mM NaCl,
1 mM MgCl2, 3 mM Mg-ATP, 4 mM EGTA (current
measurement)/0.05 mM EGTA (capacitance measure-
ment), 5 mM HEPES and 0.1 mM cAMP (capacitance
measurements) (pH 7.15 with CsOH).
Insulin secretion measurements
Insulin secretion was measured in static batch incuba-
tions described previously [25]. Briefly islets were pre-
incubated in 1 mM glucose for 30 minutes followed by
1 h incubation in extracellular solution with variable
glucose concentration. Incubation was 15 min when
50 mM KCl was used as stimulator. The extracellular
solution was supplemented with 10 μM FSK, 0.1 μM
GLP-1 (Bachem, Weil am Rhein, Switzerland), 100 μM
Tolbutamide (Sigma Aldrich, Stockholm, Sweden),
200 μM DIDS, 50 μM TMinh-AO1, 40 μM CFTRinh-
172 and/or 50 μM GlyH-101 as indicated. Insulin secre-
tion was measured using radioimmunoassay kit (mouse:
Linco Research Inc.,; human: Millipore, Billerica, MA,
USA).
Transmission electron microscopy
Islets were collected after insulin secretion assay and
prepared for electron microscopy, examined and ana-
lyzed as previously described [26]. The granule volume
density (Nv) and surface density (Ns) were calculated
using in-house software programmed in MatLab.
Statistical analysis
Data are presented as mean ± SEM of N number of individ-
uals or independent experiments and number of cells or
biological replicates. Statistical significance was calculated
using ANOVA or Student’s t test and P <0.05 was consid-
ered significant.Results
CFTR-antagonists inhibit insulin secretion and an
ATP-sensitive and cAMP-dependent current in
mouse and human beta-cells
To investigate if CFTR affects beta-cell function, the influ-
ence of CFTR on insulin secretion was measured from
isolated human and mouse pancreatic islets subjected to
glucose-induced insulin secretion assays. In human islets,
glucose caused a dose-dependent increase in insulin secre-
tion that was further enhanced by the cAMP-increasing
agent FSK. The stimulatory action of FSK at 16.7 mM
glucose was significantly reduced in the presence of the
CFTR-antagonist GlyH-101 (Figure 1A). Next we investi-
gated the effect of a more physiological elevator of cAMP,
the incretin hormone GLP-1. Like FSK, GLP-1 enhanced
insulin secretion at 16.7 mM glucose in human islets,
an effect that was completely inhibited by GlyH-101
(Figure 1B). In mouse islets, both FSK and GLP-1 amp-
lified insulin secretion stimulated by glucose was re-
duced in the presence of GlyH-101. Moreover,
CFTRinh-172, another antagonist against CFTR, also
decreased both FSK and GLP-1 enhanced insulin se-
cretion (Figures 1C, D). Both inhibitors are specific for
CFTR, and whereas CFTRinh-172 binds to the intra-
cellular domain of CFTR [23] and thereby closes the
channel, GlyH-101 is an open-channel blocker [24]. It
was confirmed that the antagonists had no significant
effect on insulin secretion at 1 mM glucose (Figure 1E)
or in presence of 16.7 mM glucose in the absence of
FSK or GLP-1 (Figure 1F). There was, though, a tendency
towards a reduction in insulin secretion by GlyH-101 in
the presence of 16.7 mM glucose alone in the human
islets. This might be due to a higher increase in cAMP
caused by glucose. It has been demonstrated that glucose
increases cAMP levels in both mouse [27] and human
[28] beta-cells. However, why the increase in cAMP gener-
ated by glucose might be higher in human islets is not
clear but could be explained by the higher number of
alpha-cells in the human islets [29,30]. cAMP is a potent
second messenger that promotes insulin secretion by
several mechanisms [19,31]. Here we establish that CFTR
has an essential and complementary function in cAMP-
amplified insulin secretion. In parallel to these findings,
we found expression of CFTR mRNA (data not shown)
and CFTR protein in both human and mouse islets
(Figure 1G).
The presence of active CFTR channels in pancreatic
beta-cells was investigated on single cells using the patch-
clamp technique in the standard whole-cell configuration.
The pipette solution contained sodium and calcium ions
in order to determine the cell-type by sodium channel
inactivation properties [32]. A voltage-ramp protocol
from −100 mV to +100 mV was applied before and
every fourth minute after the addition of FSK (10 μM)
Figure 1 Effect of CFTR inhibition on insulin secretion measured in isolated human and mouse pancreatic islets. (A) Insulin secretion
from human islets at different glucose in the absence or presence of forskolin (FSK) and GlyH-101 (GlyH) as indicated (n = 42 to 45, N = 11).
(B) Insulin secretion from human islets at 1 mM glucose (1G) or 16.7 mM glucose (16.7G) in the absence and presence of GLP-1 and GlyH-101 as
indicated (n = 17 to 19, N = 5). (C-D) Insulin secretion from mouse islets at 1 mM glucose (1G) or 16.7 mM glucose (16.7G) in the absence or
presence of FSK, GLP-1, CFTRinh-172 (CFTRinh) and GlyH-101 (GlyH) as indicated (n = 12 to 21, N = 4 to 9). (E) Insulin secretion from mouse islets
at 1 mM glucose (1G) in the absence or presence of FSK and inhibitors as indicated (n = 9–12, N = 4). (F) Insulin secretion from mouse (left) and
human (right) islets in the absence of FSK to demonstrate the lack of effect of the inhibitors (mouse: n = 10, N = 5; human n = 12, N = 3). (G)
Localization of CFTR (yellow) and insulin (red) in fixed single islet cells (left) from human (top) and mouse (bottom), detected using confocal
immunocytochemistry. Scale bar 5 μm. Images are representative of 37 beta-cells from three human donors and 23 beta-cells from three mice.
Ratio of the fraction of CFTR (right) in the plasma membrane region (P1) as compared to the cytosolic region (P2) for human (top) and mouse
(bottom) beta-cells. Data are presented as mean ± SEM. ***P <0.001 16.7 G vs 1 G, ††P <0.01 FSK or GLP-1 vs respective G alone, †††P <0.001 FSK
vs respective G alone and ‡P <0.05 CFTRinh or GlyH vs 16.7 G and FSK alone, ‡‡‡P <0.001 GlyH vs 16.7G and FSK alone.
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of FSK the current flow was minimal, whereas the increase
in intracellular cAMP induced by FSK activated a non-
linear outward rectifying current. In human and mouse
beta-cells, the cAMP-activated current was significantly
inhibited by the CFTR-inhibitors (Figure 2A-D). The
current inhibited by CFTR-inhibitors (CFTR-dependent)
constitute 47 ± 15% (n = 7) and 57 ± 7% (n = 10) of the
FSK-activated current at negative potentials, in human
and mouse beta-cells, respectively.
In addition to the ion channel function, CFTR has
been attributed a role as regulator of other ion channels
and proteins, such as other chloride channels [2,33]. To
investigate the possibility that CFTR regulates the func-
tion of other chloride channels we used the non-specific
chloride channel blocker DIDS that blocks a wide variety
of chloride channels, while CFTR is insensitive to this
antagonist [34,35]. The cAMP-stimulated current, in
human and mouse beta-cells, was significantly reduced
by DIDS (Figure 2E, F). The presence of active CFTR
channels was proven by a significant reduction in current
conductance in the simultaneous presence of GlyH-101and DIDS as compared with DIDS alone (Figure 2E, F).
The DIDS-sensitive component constituted 38 ± 10% and
CFTR 37 ± 15% (n = 5) of the FSK-activated current at
negative potentials (−100 to −50 mV) in human beta-cells.
In the mouse, the DIDS-sensitive current was 41 ± 12%
and CFTR 29 ± 9% (n = 8) of the FSK-activated current.
From these measurements the CFTR conductance was es-
timated to be 2.8 ± 0.6 pS/pF in human (n = 5; N = 3) and
12 ± 4.0 pS/pF in mouse (n = 8; N = 5) beta-cells at nega-
tive potentials (−100 mV to −50 mV). Taken together
these data indicate that 1) the cAMP-induced chloride
current has one DIDS-sensitive component and one part
sensitive to CFTR inhibition, 2) the current through CFTR
in beta-cells is small, and 3) CFTR likely acts as a regula-
tor of DIDS-sensitive chloride channel(s).
CFTR likely regulates the chloride channel
Anoctamin 1 (ANO1)
The suggestion that CFTR can act as a regulator upstream
of other chloride channels involved in the regulation of
insulin release was verified through the investigation of
the combined effect of DIDS and GlyH-101 on insulin
Figure 2 cAMP-activated chloride currents in human and mouse beta-cells. (A) Currents measured in a single human beta-cell after stimulation
with voltage ramps in the absence (Ctrl, light gray) and presence of forskolin (FSK; gray), in the simultaneous presence of FSK and GlyH-101 (FSK and
GlyH; black) and after wash-out of GlyH-101 to recover the FSK-activated current (WO: FSK; dark gray). Current ramps were applied before and every
fourth minute after the application of FSK until a steady state was achieved. (B) Bar graph of the membrane conductance at negative voltages
(left; n = 7 to 17, N = 3) and graph of calculated FSK-activated and CFTR-dependent current (right; Mean of n = 7 cells) from data in A. (C) Same
as in A, but experiments where performed on mouse beta-cell. GlyH-101 (GlyH: black trace) and CFTRinh-172 (CFTRinh, black) was added to the
left and right, as indicated. (D) As in B, but membrane conductance (left) was calculated from data in C (n = 10 to 17, N = 8). The mean result
was combined for both CFTR-inhibitors (Inh). The calculated FSK-activated and CFTR-dependent current to the right is a mean from 10 cells. (E)
As in A, but the effect of 4,4'-Diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS) was investigated (n = 6, N = 2). Calculated FSK-activated, DIDS-sensitive
and CFTR-currents shown to the right are mean of n = 5 cells. (F) Same as in E, but the membrane conductance (left) was calculated from
measurements in mouse beta-cells (n = 9, N = 6) and the calculated current to the right is the mean from n = 8 cells. Data are presented as
mean ± SEM. *P <0.05, ***P <0.005, ‡ P <0.05, ‡‡‡P <0.005, †P <0.01 and ††P <0.01.
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of tolbutamide to circumvent that DIDS might affect the
ATP-dependent potassium channel [36]. At high con-
centrations tolbutamide can inhibit CFTR currents [37],
but at the concentration used here (100 μM) the major
influence is on the closure of the ATP-dependent potas-
sium channel. This was confirmed by insulin secretion
measurements showing that tolbutamide increased (rather
than decreased) insulin secretion at 16.7 mM glucose in
mouse islets, while no further stimulation of insulin secre-
tion was observed in human islets (Figure 3A, B). This is
most likely due to the different sensitivity of glucose inmouse and human islets and in line with previous results
[38,39]. In the presence of tolbutamide, GLP-1-enhanced
glucose-stimulated insulin secretion was significantly re-
duced in the presence of DIDS (Figure 3A, B), in both
mouse and human islets. The addition of GlyH-101 in the
continued presence of DIDS did not further reduce the
secretory response in mouse beta-cells as compared to
DIDS alone (Figure 3A), suggesting that CFTR regulates a
DIDS-sensitive chloride channel.
Recently, it was suggested that channels from the family
of Anoctamins (ANO1-10) are controlled by CFTR [40,41].
The first member in this family, ANO1, is a voltage- and
Figure 3 The combined effect of chloride channel blockers on GLP-1 enhanced GSIS. (A) Insulin secretion from mouse islets after 1 h
incubation in 1 mM glucose (1G), 16.7 mM glucose (16.7G), tolbutamide (Tlb), GLP-1, DIDS- and GlyH-101 as indicated (n = 12 to 20, N = 4).
(B) The same as in A, but insulin secretion was measured from human islets (n = 20 to 28, N = 5). (C) As in A, but the impact of the anoctamin 1
inhibitor TM16Ainh-AO1 (AO1) on GLP-1 enhanced insulin secretion was investigated in mouse islets (n = 14, N = 3). (D) As in C, but experiments
were performed on human islets (n = 4, N = 1). (E) As in C, but the effects of forskolin (FSK) and AO1 was investigated at 1 mM glucose as
indicated. Data are presented as mean ± SEM., **P <0.01, ***P <0.005, †P <0.05, †††P <0.005, ‡P <0.05, ‡‡P <0.01, ‡‡‡P <0.005 ¶¶P <0.01. (F) Bar
graph of membrane conductance at negative (left) membrane potentials in the absence and presence of FSK, TM16Ainh-AO1 (AO1) and
GlyH-101 (GlyH) (n = 6, N = 4). Calculated FSK-activated, AO1-sensitive and CFTR-currents shown to the right are mean of n = 5 cells. Data are
presented as mean ± SEM. *P <0.05, ‡P <0.05, ‡‡P <0.01.
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plasma membrane that has been suggested to interact
with CFTR to control chloride conductance in epithelial
cells [41]. Interestingly, ANO1 gene expression has been
measured in rat and human islets [42,43]. To investigate
the possible combined involvement of ANO1 and CFTR
in the regulation of insulin secretion we performed insulin
secretion measurements in mouse and human islets in the
presence or absence of specific blockers of the respective
channel. Indeed, insulin secretion enhanced by GLP-1 was
reduced by TM16Ainh-AO1 (AO1), a specific blocker of
ANO1 [44], and in the combined presence of GlyH-101
and AO1 the reduction in GLP-1 enhanced glucose-
stimulated insulin secretion was not significantly different
from the reduction observed after application of either of
them alone (Figure 3C, D). In human islets, the inhibitory
effect of AO1 was significantly more potent than GlyH-
101 alone, but, as in the mouse, inclusion of GlyH-101 in
the simultaneous presence of AO1 did not cause an
additive decrease in GLP-1 amplified insulin secretion
at 16.7 mM glucose (Figure 3D). It was confirmed that
AO1 did not have any inhibitory effect at 1 mM glucose
(Figure 3E).
The presence of ANO1 chloride current in beta-cells
was measured by patch-clamp recordings on single mousebeta-cells using the standard whole-cell mode and the
ramp-protocol as used above. It was obvious that the
FSK-activated current was reduced by AO1, and the
conductance was decreased (Figure 3F). A small, but
significant, further reduction in conductance was obtained
in the simultaneous presence of AO1 and the CFTR-
inhibitor GlyH-101 (Figure 3F). The AO1-sensitive current
was calculated to represent 50 ± 10% and CFTR 30 ± 5% of
the FSK-activated current at negative potentials (n = 5). The
CFTR conductance was estimated to 14 ± 3 pS/pA (n = 5).
Interestingly, these are similar to values obtained from the
DIDS-experiments in Figure 2 (12 pS/PA and 29%). This
experiment demonstrates that the blockers AO1 and GlyH-
101 most likely act on separate channels (Figure 3E).
Hence, the lack of an additive effect on secretion (Figure 3C,
D) would suggest that CFTR interacts with ANO1 in regu-
lating insulin secretion.
Inhibition of CFTR results in decreased exocytosis in
mouse and human beta-cells
We were next interested in investigating mechanisms by
which CFTR and ANO1 influence insulin secretion.
Insulin secretion comprises a cascade of events often
referred to as the “stimulus-secretion-coupling” [45].
Briefly, glucose uptake and metabolism yields ATP,
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ing of voltage sensitive calcium channels and increased
levels of intracellular calcium resulting in exocytosis of
insulin granules. Theoretically, CFTR could be involved in
any of these steps. Indeed, it has been suggested that an
ATP-sensitive and cAMP-activated chloride current influ-
ences the membrane depolarization and electrical activity
of insulin secreting cells [17]. We found that CFTR-
inhibition reduced insulin secretion under conditions
independent of cellular metabolism and membrane
depolarization (Figure 4A), suggesting a possible func-
tion of CFTR in the downstream exocytotic process.
To elaborate further on this, capacitance recordings
were performed on single beta-cells in the presence of
ATP and cAMP in the intracellular solution. Exocyt-
osis, evoked by a train of 10 500-ms depolarizations
from −70 mV to 0 mV, was significantly reduced in human
beta-cells pre-incubated with GlyH-101 (Figure 4B, C).
The reduction in membrane capacitance increase was
most prominent during the first two depolarizations
reflecting rapid exocytosis of primed granules [46]. The
exocytotic response in mouse beta-cells was likewise
reduced after CFTR-inhibition (Figure 4D, E). Next,Figure 4 Effect of CFTR inhibition on depolarization evoked secretion
after 15 minutes incubation at 1 mM glucose (1G) in the presence of 50 m
(GlyH) as indicated. Data are presented as mean ± SEM of n = 15 to 17, N =
measured as an increase in membrane capacitance (ΔCm; bottom left) und
with GlyH-101 (GlyH; right). Experiments were conducted in the presence o
n = 6 and GlyH; n = 4). *P <0.05. Data are presented as the increases in memb
pulses (∑1–2) or the latter eight pulses (∑3–10). (D) As in B, but the increase in m
CFTRinh-172 (CFTRinh) was used as an inhibitor of CFTR. (E) Summary of data
as in C. (F) Inward voltage-dependent current in a single human beta-cell
relationship of voltage-dependent currents (right). Data are mean ± SEM o
GlyH-101. (G) As in F, but experiments were conducted on mouse beta-ceeffects on voltage-dependent calcium currents were inves-
tigated. The current was evoked by 50-ms depolarizations
from −70 mV to voltages between -50 and +50 mV in
single human or mouse beta-cells and in the presence
and absence of GlyH-101 or CFTRinh-172, respectively
(Figure 4F, G). The intracellular solution was supple-
mented with cAMP to activate CFTR. The currents
comprise a rapid sodium current followed by a more slowly
opening calcium current. The charge was measured as the
integral of the current and reflected the influx through the
calcium channels. From the data we could conclude that
the calcium current was not affected by CFTR inhibition
(Figure 4F, G), suggesting a direct effect on the exocytotic
machinery [21]. Interestingly, DIDS has earlier been dem-
onstrated to reduce insulin exocytosis, an effect that has
been coupled to intragranular ClC3 chloride channels and
priming of the insulin granules [47], implying that CFTR
can act by controlling ANO1 to influence priming and exo-
cytosis. Depolarization-evoked exocytosis of primed gran-
ules is hypothesized to correspond to first phase insulin
secretion [46], thus suggesting an important role of CFTR
at this stage. Indeed, patients with CF exhibit reduced first
phase insulin secretion [9,15,16].and exocytosis. (A) Insulin secretion from mouse islets measured
M KCl (K), 10 μM forskolin (FSK), CFTR-inh172 (CFTRinh) and GlyH-101
4. ††P <0.01, ‡P <0.05. (B) Exocytosis in single human beta-cells
er control conditions (Ctrl; left) and after 10 minutes pre-incubation
f cAMP in the intracellular solution. (C) a summary of data in B (Ctrl;
rane capacitance evoked by all 10 pulses of the train (∑all), the two first
embrane capacitance was measured on single mouse beta-cells and
in D (Ctrl; n = 10 and CFTRinh-172; n = 7). ***P <0.001. Data are presented
in the presence and absence of GlyH-101 (left) and charge-voltage
f 10 control experiments and 5 experiments in the presence of
lls (Control; n = 7 and CFTRinh-172; n = 11).
Edlund et al. BMC Medicine Page 8 of 122014, 12:87
http://www.biomedcentral.com/1741-7015/12/87The above results prompted us to investigate granular
docking using TEM, since docking of the granules to the
plasma membrane is vital for exocytosis. Mouse islets
were subject to incubation in 1 mM glucose, 16.7 mM
glucose in the absence and/or presence of FSK and
GlyH-101 prior to fixation (Figure 5A). We performed
ultrastructural analysis and estimated the granule volume
density per cell, Nv, and the surface density per cell, Ns,
from the micrographs. Nv and Ns are proportional to the
total number of granules and the number of docked gran-
ules, respectively. The total number of granules within the
beta-cells was not changed between islets treated under
the different conditions (Figure 5B). Glucose signifi-
cantly increased the docked pool (Ns) in agreement with
previous observations that glucose enhances granule refill-
ing and mobilization [48]. Addition of FSK caused a
reduction in the number of docked granules, confirming
earlier electrophysiological observations that mobilization
is rate-limiting [49]. Finally, the docked pool of granules
was significantly reduced in beta-cells incubated with
GlyH-101 and FSK, as compared to FSK alone (Figure 5C).Figure 5 Consequences on ultrastructural parameters after CFTR inhi
after incubation for one hour as indicated. The area within the dotted rectang
indicated by a black solid line. The granules where defined as docked when t
membrane (dashed line). N = nucleus. Scale bars: 2 μM (left) and 0.5 μM (right
density (Nv; granules*μm-3) after incubation in 1 mM glucose (1 G), 16.7 mM
indicated in the color coding in D. (C) Bar graph of the docked granules as es
conditions as in D. (D) Relative distribution of granules at distance fractions fro
Color-coding for the different conditions is at the top right (n = 43 to 45 c
mean ± SEM. **P <0.01 16.7 G vs 1 G, ***P <0.001 16.7 G vs 1 G †P <0.05 FSK
16.7 G and FSK alone, ‡‡‡P <0.001 GlyH vs 16.7 G and FSK alone. (E) Localiz
single human islet cells detected using confocal immunocytochemistry (le
membrane is shown to the right. The images are from a representative ceMoreover, it is evident from the analysis that only the frac-
tion of granules within 300 nm from the plasma mem-
brane is affected by inhibition of CFTR (Figure 5D). This
is in accordance with a role for CFTR in docking and
priming of insulin granules.
CFTR has been shown to act through additional mecha-
nisms, one being interaction with the SNARE-protein
syntaxin 1A [50,51], a protein crucial for beta-cell granule
docking and exocytosis [46]. To investigate the possibility
that CFTR interacts with this SNARE-protein, we inves-
tigated the distribution of CFTR and syntaxin 1A, and
found that CFTR was co-localized with syntaxin 1A in
the plasma membrane of human beta-cells (86 ± 2% co-
localization, n = 39; N = 2; Figure 5E).
Discussion
Chloride channels play key roles in pancreatic beta-cells
[17,52-54], but the exact identity of all chloride channels
involved remains to be established. A previous study in-
dicated that endocrine cells in the rat pancreas express
the mRNA encoding CFTR [18]. Here we provide novelbition. (A) Electron micrographs of a single beta-cell within an islet
le in the left image is highlighted to the right. The plasma membrane is
he center of the granule was located within 150 nm from the plasma
). (B) Bar graph of the total number of granules measured as volume
glucose (16.7 G), 10 μM forskolin (FSK) and 50 μM GlyH-101 (GlyH) as
timated by the surface density (Ns; granules*μm−2) under the different
m the PM. The distance at the x-axis is the upper border of each fraction.
ells, N = 3 animals per condition). For B-D, data are presented as
vs 16.7 G alone, ††P <0.01 FSK vs 16.7 G alone, ‡P <0.05 GlyH vs
ation of CFTR (yellow), syntaxin 1A (red) and insulin (green) in fixed
ft). A bar graph describing the measured co-localization in the plasma
ll out of 39 from two human donors.
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important functions in human and mouse beta-cells
[17,52-54], and suggest that CFTR acts upstream of
ANO1 [2,33,41] to control insulin secretion.
In a previous study, Kinard and Satin [17] measured an
ATP- and cAMP-dependent chloride current in insulin
secreting cells that could be activated under hypotonic
conditions. The current was termed ICl,islet and had
similar properties in terms of size and reversal potential
as the chloride current obtained here in the presence of
glucose and FSK/GLP-1 (Figure 2). It was suggested
[17] that the ICl,islet contributes to cAMP-dependent
depolarization at negative membrane potentials although
the exact identity of the channel was not described. It has
been suggested that the channel is a volume-regulated
anion channel (VRAC; [55]), due to similarities with ICl,islet
in terms of activation and electrophysiological properties.
Our focus was CFTR and we did not investigate the pres-
ence of a current sensitive to cell swelling. However, our
data do not rule out the presence of VRAC. Whereas
VRAC is suggested to enhance electrical activity, we
hypothesize that the main function of CFTR/ANO1 is in
the control of exocytosis. We confirm that activation of
the ATP- and cAMP-dependent chloride current con-
tributes to a small depolarization at potentials below the
equilibrium potential for chloride, when the flux of
chloride ions is outward from the cell comparable to the
depolarization obtained by cAMP on electrical activity
measured on whole islets [56,57].
The measured current conductance in the presence of
FSK varies among different batches of cells investigated
and amounts between approximately 80 and 120 pS/pF
and approximately 20 and 40 pS/pF in mouse beta-cells
(Figures 2B, F and 3F) and human beta-cells (Figure 2B, E),
respectively. Biological variation is common in studies on
primary tissue and human primary tissue in particular.
However, more importantly, the estimated CFTR conduct-
ance after blockade of other chloride-currents using DIDS
or by blocking ANO1 becomes the same (13 pS/pF and 12
pS/pF, respectively), strongly supporting the presence of a
CFTR conductance. Although small, the impact on insulin
secretion is large, suggesting that CFTR has a function up-
stream of many other cAMP-activated processes involved
in insulin secretion [19,27,49,56,58].
We provide evidence suggesting that the main conse-
quence of the cAMP-activated chloride current is unrelated
to membrane depolarization (Figure 4A). More specifically
our studies point to a role of CFTR and ANO1 in cAMP
augmented calcium-dependent exocytosis. Indeed, both
FSK- and GLP-1-enhanced, glucose-stimulated insulin
secretion is reduced by CFTR-inhibitors. We observed
that the inhibitors are more potent on GLP-1 than on
FSK-stimulated secretion. This we mainly attribute to
the fact that FSK increases cAMP to a higher level thanGLP-1 in islets (see, for example, [19]). The participation
of CFTR in the exocytotic process is supported by the cap-
acitance measurements showing that exocytosis is blocked
by CFTR-inhibitors in both human and mouse beta-cells
(Figure 4). Exocytosis is a calcium-dependent process and
the reduced exocytotic response observed in the presence
of the CFTR antagonists might be explained by a reduced
calcium current [59], but this was proven not to be the
case (Figure 4F, G). Based upon our observations from
insulin secretion and electrophysiological ramp-protocol
measurements we instead hypothesize that CFTR through
ANO1 act directly on exocytosis. Indeed, we found CFTR
to co-localize with the SNARE-protein syntaxin 1A
(Figure 5E) as demonstrated in other tissues [50,51].
This suggests that CFTR, as syntaxin 1A, is part of the
exocytotic machinery.
From our novel results we suggest that CFTR plays a
key role in priming of the insulin granules; this is evident
from the capacitance measurements and the electron
micrographic data. The increase in membrane capacitance
evoked by a train of membrane depolarizations initiates
exocytosis of release-ready (primed) granules by the first
two depolarizations, whereas the latter depolarizations en-
able granules within a larger reserve pool to be released
[46]. Our data demonstrate a pronounced reduction in
exocytosis evoked during the two first depolarizations
(Figure 4B-E). Hence, CFTR can be suggested to have its
main function in the priming of insulin granules. More-
over, the ultrastructural analysis revealed that the number
of granules in close vicinity to the plasma membrane
(<300 nm) was reduced after CFTR inhibition (Figure 5D).
The exact molecular mechanism by which CFTR contrib-
utes to granular priming is hitherto unknown. Interestingly,
DIDS has earlier been demonstrated to reduce insulin exo-
cytosis, an effect that has been coupled with intragranular
ClC3 chloride channels and priming of the insulin granules
[47]. A role for ClC3 in insulin granular priming and
exocytosis has also been proven by knock-out animals
[54]. Here we demonstrate that CFTR inhibition reduces
exocytosis to the same extent as has earlier been demon-
strated for DIDS [47] and removal of ClC3 [54]. As DIDS
is a chloride channel blocker inhibiting the current
through most chloride channels except for CFTR, the
ANO1 current is likely reduced by this treatment (com-
pare Figures 2F and 3F). Our insulin secretion measure-
ments and chloride current measurements suggest that
CFTR acts on ANO1. The mechanisms by which ANO1
is regulated by CFTR is yet to be investigated, but the
small influx of chloride through CFTR seems to have
some function since the ANO1 current was inhibited
by the CFTR-specific open-channel blocker Gly-H 101
(Figure 3F). The fact that ANO1 is calcium activated
[41] is consistent with a role of this channel in exocyt-
osis. It can be argued that the increase in cAMP will
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thereby increase the ANO1 current and insulin secretion.
This process can most likely occur in parallel with the
cAMP-dependent regulation of ANO1 via CFTR as dem-
onstrated here. Our data, however, demonstrate a role for
CFTR in regulating insulin secretion through a direct ef-
fect on exocytosis.
Conclusions
As illustrated in the model in Figure 6, we propose partici-
pation of CFTR, ANO1 and ClC3 in the same process and
suggest that ion-fluxes through these ion channels together
contribute to improved beta-cell exocytosis and priming.
We hypothesize that cAMP activates CFTR, in addition to
parallel activation of proteins already known to be import-
ant for insulin granule exocytosis. These include PKA that
is stimulating calcium influx [58] and granular mobilization
[49] and Epac2, which are involved in granular priming
[19]. Epac2 is in complex with SUR1 and the granular ClC3
chloride channel [19,54]. We postulate that CFTR via
ANO1 provides granular ClC3 chloride channels with
chloride ions necessary to improve cAMP-dependent
granular priming, exocytosis and secretion. This is possible
since the flux of chloride ions changes during an action
potential and is inward above the equilibrium potential
for chloride. Thus, the direction of the chloride flux is
into the cell at potentials needed to initiate exocytosis
(above approximately −20 mV).Figure 6 Model describing a possible involvement of CFTR in
beta-cell granular priming and exocytosis. High glucose
increases intracellular ATP leading to depolarization and influx of
intracellular calcium triggering exocytosis. GLP-1 and forskolin (FSK)
increase intracellular cAMP, which, together with the increase in ATP,
enhance the priming of insulin granules, a process that involves
influx of chloride into the granules through the intragranular ClC3
channels. Our data indicate that cAMP and ATP in parallel activate
CFTR. We suggest that CFTR through a still unknown mechanism
regulates ANO1 and hypothesize that the influx of chloride through
ANO1 supplies the intragranular ClC3 channel and thereby enhances
granular priming. CFTR, Cystic Fibrosis Transmembrane conductance
regulator; ANO1, Anoctamin 1 chloride channel; gSUR, granular
sulfonylurea receptor; Ca2+, calcium.Depolarization-evoked exocytosis of primed granules
is hypothesized to correspond to the first phase insulin
secretion [46], suggesting an important role for CFTR at
this stage. Indeed, many CF patients suffer from post-
prandial hyperglycemia although they have normal fast-
ing plasma glucose levels indicating that the beta-cells
fail to respond upon increased insulin demand. For these
patients, impaired insulin secretion is mostly apparent
during the first phase, strongly indicating a defect at the
level of the pancreatic beta-cell [9,14-16]. The impaired
insulin secretion has been suggested to be due to se-
vere exocrine tissue damage destroying the beta-cells
[4,10,11,13,15], but others have indicated direct effects
on beta-cell function [9,15,16,60,61]. Indeed, reduced
or absent acute insulin response to glucose in patients
with CFRD was recently shown to be compensated by
pharmacological CFTR potentiation [16]. Here we provide
a likely explanation to the clinical observations supporting
an effect on beta-cell function. We demonstrate for the
first time that CFTR has a role at the cellular level, in both
human and mouse beta-cells, by regulating insulin secre-
tion. Specifically, we provide evidence that interference
with CFTR affects cAMP-dependent rapid exocytosis of
primed granules important for first phase insulin release.
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